Abingworth raised $105 million for its first dedicated clinical co-development fund.
Avexis Inc. filed to raise up to $115 million from an IPO.
Beigene Co. Ltd. set terms for its IPO, which will seek to raise $126.5 million by offering 5.5 million American depositary shares, each representing 13 ordinary shares, priced in a range of $22 to $24.
CASI Pharmaceuticals Inc. received approximately $10.1 million from a strategic financing.
Essa Pharma Inc. completed its private placement for gross proceeds of $15 million.
Oncobiologics Inc. filed to raise up to $115 million in an IPO.
Vasopharm GmbH raised $21.7 million in a new funding round.
Abbvie Inc. is working with the University of Texas MD Anderson Cancer Center in a three-year collaboration focused on immuno-oncology.
Acorda Therapeutics Inc. is acquiring Biotie Therapies Oyj for $363 million in cash.
Basilea Pharmaceutica Ltd. said it was informed that Glaxosmithkline plc is discontinuing its U.S. Toctino (alitretinoin) program.
Galapagos NV and Gilead Sciences Inc. closed their license and collaboration agreement on filgotinib, triggering the up-front license fee of $300 million by Gilead.
Irx Therapeutics Inc. and Immunid Technologies SAS inked a collaborative agreement to research IRX-2 using Immunid's Immuntracker.
Kedrion Biopharma Inc. gained exclusive rights to commercialize the immunoglobulin brand Bivigam, a 10 percent liquid licensed by Biotest Pharmaceuticals Corp., a unit of Biotest AG.
Mannkind Corp. is collaborating with Receptor Life Sciences Inc. to explore multiple inhaled therapeutic products for the potential treatment of chronic pain, neurologic diseases and inflammatory disorders.
Regen Biopharma Inc. is collaborating with the National Center for Advancing Translational Sciences to jointly explore the biology of the NR2F6 protein.
Upsher-Smith Laboratories Inc., through its subsidiary Proximagen Ltd., inked a deal with Saniona AB to discover and develop small-molecule therapeutics for neurological disorders.
. . . AND MORE
Biocad Biotechnology Co. received approval from Russian regulators for a biosimilar of Herceptin (trastuzumab, Roche AG).
Ico Therapeutics Inc. said it initiated a strategic reorganization to preserve cash.
Italy's successful biotech entrepreneurs are forming the Italian Angels for Biotech, which aims to support the emergence of a new generation of start-ups in Italy.
Kuros Biosciences Ltd. closed the acquisition of Kuros Biosurgery Holding Ltd. and changed the name of the combined company to Kuros Biosciences.
Loxo Oncology Inc. said the EMA granted orphan drug designation for LOXO-101 to treat patients with soft tissue sarcoma.
Galapagos NV and Abbvie Inc. plan to advance a triple cystic fibrosis transmembrane conductance regulator program that will address 90 percent of patients with the disease.
Medicinova Inc. said the FDA granted MN-166 (ibudilast) rare pediatric disease designation to treat type I, early infantile Krabbe disease.
Novartis AG said the FDA approved Cosentyx (secukinumab), an interleukin-17a inhibitor, for the treatment of two new indications: adults with active ankylosing spondylitis and active psoriatic arthritis.
Nivalis Therapeutics Inc. received FDA orphan designation for N91115, a stabilizer of the cystic fibrosis transmembrane conductance regulator protein.
Samsung Bioepis Co. Ltd. got the first EU approval for biosimilar etanercept.